Resumen

Objective: To assess the effect of exenatide once weekly on metabolic and glycemic control in patients with prediabetes. Methods: This was a quasi-experimental study in eight patients with prediabetes without pharmacological treatment. Exenatide (2 mg) once weekly was administered subcutaneously for 12 weeks. Measurements of metabolic and glycemic control were done before and after pharmacological intervention. Differences at baseline and final measurements were tested using Wilcoxon signed-rank test. P ≤ 0.05 was considered significant. Results: After pharmacological intervention, a significant decrease in body weight (82.5 ± 9.1 vs. 80.6 ± 8.9 kg; p = 0.012), body mass index (31.5 ± 3.7 vs. 30.8 ± 3.7 kg/m²; p = 0.012), waist circumference (101 ± 8 vs. 97 ± 7 cm; p = 0.017), and systolic blood pressure (127 ± 7 vs. 121 ± 7 mmHg; p = 0.021), as well as fasting plasma glucose (6.1 ± 0.4 vs. 5.3 ± 0.9 mmol/l; p = 0.028) and glycated hemoglobin (A1C) (5.7 ± 0.4 vs. 5.4 ± 0.4%; p = 0.046) were observed. Conclusion: Administration of exenatide once weekly for 12 weeks significantly decreases body weight body mass index, waist circumference and systolic blood pressure as well as fasting plasma glucose and glycated hemoglobin (A1C) in patients with prediabetes.

Palabras clave: Exenatide glycemic control metabolic control prediabetes

2017-05-24   |   410 visitas   |   Evalua este artículo 0 valoraciones

Vol. 3 Núm.4. Octubre-Diciembre 2016 Pags. 169-174 Rev Mex Endocrinol Metabol Nut 2016; 3(4)